Risedronate

Usual Dosing (Adults)

Treatment of Postmenopausal Osteoporosis:
one 5 mg tablet orally, taken daily or one 35 mg tablet orally, taken once a week or one 75 mg tablet orally, taken on two consecutive days for a total of two tablets each month or one 150 mg tablet orally, taken once a month

Prevention of Postmenopausal Osteoporosis: one 5 mg tablet orally, taken daily or one 35 mg tablet orally, taken once a week or alternatively, one 75 mg tablet orally, taken on two consecutive days for a total of two tablets each month may be considered or alternatively, one 150 mg tablet orally, taken once a month may be considered

Treatment to Increase Bone Mass in Men with Osteoporosis: one 35 mg tablet orally, taken once a week .

Treatment and Prevention of Glucocorticoid-Induced Osteoporosis: one 5 mg tablet orally, taken daily.

Treatment of Paget’s Disease: The recommended treatment regimen is 30 mg orally once daily for 2 months. Retreatment may be considered (following post-treatment observation of at least 2 months) if relapse occurs, or if treatment fails to normalize serum alkaline phosphatase. For retreatment, the dose and duration of therapy are the same as for initial treatment. No data are available on more than 1 course of retreatment

Renal Dosing

ACTONEL is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Hemodialysis

ACTONEL is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.